This study supports AXL as a mediator of intrinsic resistance to ROS1 targeted therapy and highlights the need for further studies on AXL‐targeted therapies in ROS1 TKI resistant NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.